These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 30049849)
1. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Chebib FT; Torres VE Clin J Am Soc Nephrol; 2018 Nov; 13(11):1765-1776. PubMed ID: 30049849 [TBL] [Abstract][Full Text] [Related]
2. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease. Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E; BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514 [TBL] [Abstract][Full Text] [Related]
3. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. Chebib FT; Torres VE Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818 [TBL] [Abstract][Full Text] [Related]
4. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon. Zhou JX; Torres VE Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527 [TBL] [Abstract][Full Text] [Related]
5. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543 [TBL] [Abstract][Full Text] [Related]
7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
8. Clinical Manifestation and Management of ADPKD in Western Countries. Sommerer C; Zeier M Kidney Dis (Basel); 2016 Oct; 2(3):120-127. PubMed ID: 27921039 [TBL] [Abstract][Full Text] [Related]
9. Review of tolvaptan for autosomal dominant polycystic kidney disease. Baur BP; Meaney CJ Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579 [TBL] [Abstract][Full Text] [Related]
10. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?]. Cornec-Le Gall E; Le Meur Y Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related]
12. [Tolvaptan, a vasopressin V Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456 [TBL] [Abstract][Full Text] [Related]
13. An update on tolvaptan for autosomal dominant polycystic kidney disease. Poch E; Rodas L; Blasco M; Molina A; Quintana L Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Ackley W; Dahl NK; Park M Adv Kidney Dis Health; 2023 May; 30(3):228-235. PubMed ID: 37088525 [TBL] [Abstract][Full Text] [Related]
15. Autosomal dominant polycystic kidney disease: time for a change? Chapman AB J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048 [TBL] [Abstract][Full Text] [Related]
17. [ADPKD treatment: Tolvaptan and Octreotide]. Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392 [TBL] [Abstract][Full Text] [Related]
18. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model. Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065 [TBL] [Abstract][Full Text] [Related]
19. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease. Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376 [TBL] [Abstract][Full Text] [Related]
20. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]